[Retracted] Impact of HSP90α, CEA, NSE, SCC, and CYFRA21-1 on Lung Cancer Patients

Table 1

Correlation between plasma HSP90α concentration and various clinical pathological parameters of lung cancer.

Pathological feature	Number of cases	HSP90α (ng/ml)
Male	53	89.77 ± 55.03	0.2
Female	25	99.69 ± 63.76	0.2
Age ≥  65	39	84.57 ± 58.52	0.4
Age ＜ 65	39	101.32 ± 56.46	0.4
Smoking—yes	41	86.61 ± 51.75	0.88
Smoking—no	37	84.77 ± 54.31	0.88
Left side	34	93.95 ± 67.03	0.8
Right side	44	92.17 ± 50.21	0.89
Adenocarcinoma	45	85.03 ± 47.87	0.5
Small cell	10	147.67 ± 47.00	0.4
Squamous carcinoma	22	78.27 ± 53.64	0.6
Giant cell	1	225.39	0.621
Degree of differentiation (DoD)
High DoD	17	67.90 ± 37.57	0.608
Moderate DoD	22	81.28 ± 47.49	0.624
Poor DoD	28	90.06 ± 55.37	0.689
Undifferentiated	11	154.74 ± 67.74	0.749
1.	26	64.98 ± 38.67	0.7
2.	8	64.91 ± 15.87	0.68
3.	18	89.15 ± 47.92	0.6
4.	26	132.18 ± 66.82	0.6
Lung metastasis—yes	11	113.75 ± 69.92	0.04
Lung metastasis—no	62	80.65 ± 49.34	0.04
Lymph node metastasis (LNM)—yes	44	89.52 ± 48.38	0.081
LNM—no	35	81.26 ± 57.67	0.081
Bone metastasis (BM)—yes	14	111.38 ± 51.02	0.01
BM—no	65	81.37 ± 52.07	0.01